Eli Lilly (LLY) Gains from Investment Securities (2009 - 2026)

Eli Lilly (LLY) has reported Gains from Investment Securities for 18 consecutive years, with $297.0 million the latest figure, recorded in Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $297.0 million, up 367.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 134.57% YoY), and the FY2025 annual result was $645.0 million, down 4.73% from the prior year.
• Gains from Investment Securities was $297.0 million for Q1 2026 at Eli Lilly, down from $589.2 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $971.9 million in Q3 2023 and troughed at -$456.8 million in Q2 2023.
• Average Gains from Investment Securities over 5 years is $173.5 million, with a median of $151.9 million recorded in 2024.
• Year-over-year, Gains from Investment Securities soared 509.13% in 2022 and slumped 1966.97% in 2023.
• Over 5 years, Gains from Investment Securities stood at $266.1 million in 2022, then fell by 3.72% to $256.2 million in 2023, then slumped by 40.71% to $151.9 million in 2024, then soared by 287.89% to $589.2 million in 2025, then plunged by 49.59% to $297.0 million in 2026.
• Per Business Quant data, the three most recent Gains from Investment Securities figures were $297.0 million in Q1 2026, $589.2 million in Q4 2025, and -$312.1 million in Q3 2025.